Practical aspects of the use of topiramate in patients with epilepsy

Epilepsia

Volumn 38, Issue SUPPL. 1, 1997, Pages

  Sander, J W A S ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Anticonvulsants; Drug toxicity; Topiramate

Indexed keywords

ANTICONVULSIVE AGENT; TOPIRAMATE;

CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; EPILEPSY; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 0030950105     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1997.tb04521.x     Document Type: Conference Paper

References (8)

1. Faught E, Wilder BJ, Ramsay RE. et al. Topiramate placebocontrolled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996;46:1684-90.
2. Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-. and 1,000-mg daily dosages. Neurology 1996;46:1678-83.
3. Ben-Menachem E, Henriksen O. Dam M. et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:539-43.
4. Sachdeo R, Reife R, Lim P. Pledger G. Single-center topiramate monotherapy trial. Epilepsia 1995;36(suppl 3):151.
5. Biton V. Preliminary open-label experience with topiramate in primary generalized seizures, Epilepsia 1997;38(suppl 1):S42-5 (this issue).
6. Espe-Lillo J, Ritter FJ, Frost MD, Spiegel RH, Reife R. Topiramate in childhood epilepsy: titration, adverse events, and efficacy in multiple seizure types. Epilepsia 1995;36(suppl 4):56.
7. Shorvon S. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996;37(suppl 2):S18-22.
8. Bourgeois BFD. Drug interaction profile of topiramate. Epilepsia 1996;37(suppl 2):S14-7.